Acomhal Research

Acomhal Research is a private, preclinical-stage biotech founded in 2018 and headquartered in San Diego, CA, USA, with an additional operational address in Roanoke, VA. The company is developing a novel peptide therapeutic designed to target and disrupt chemo-resistant cancer cells and cancer stem cells, aiming to prevent relapse and metastasis as an adjunct to existing treatments. It has secured non-dilutive funding through multiple SBIR/STTR grants and was part of the Johnson & Johnson Innovation JLABS cohort, positioning it for early-stage validation and partnership opportunities.

Proprietary peptide-based platform designed to target and disrupt chemo-resistant cancer cells and cancer stem cells by interfering with specific tumorigenic signaling mechanisms that promote resistance and metastasis.

The field of targeting cancer stem cells and treatment-resistant populations is crowded and highly competitive, involving large pharma, biotech startups, and academic institutions. Acomhal's differentiation lies in its specific peptide approach and adjunct therapy strategy, but it must compete for funding, partnerships, and ultimately, clinical validation against other modalities like antibodies, small molecules, and immunotherapies aimed at the same problem.